Beneficial effect of a diet containing heat-killed Lactobacillus paracasei K71 on adult type atopic dermatitis

Abstract

The purpose of this study was to investigate the clinical effect of a supplementary diet containing heat-killed lactic acid bacterium Lactobacillus paracasei K71 (LAB diet) on adult patients with atopic dermatitis (AD). A randomized, double-blind, placebo-controlled study was conducted in 34 adult type AD subjects who were treated with conventional topical corticosteroid and tacrolimus. LAB diet or placebo was added over 12 weeks. The primary end-point was the clinical severity of AD which was evaluated by a severity scoring system proposed by the guideline of the Japanese Dermatological Association. The effect was also secondarily evaluated by itch scores of visual analog scales (VAS), quality-of-life (QOL) impairment scores of Skindex 16 and consumption amounts of topical therapeutics. Data on these four assessment variables were collected at baseline and at week 4, 8 and 12. Within the study population, the skin severity scores were significantly decreased from baseline at week 8 (P<0.05) and at week 12 (P<0.01) in the LAB diet group but not in the placebo group. Influence of LAB diet on itch scores or QOL impairment scores was not evident. The consumption of topical therapeutics in the placebo group was 1.9-times greater in total amount compared with the corresponding value in the LAB diet group during the intervention period, although there was no significant difference. No LAB diet- or placebo-related adverse events were observed. We concluded that the LAB diet may have some benefits as a complementary therapy for adult AD patients who are managed with the conventional treatment.

Scoping systematic review of treatments for eczema

“…A government-funded trial carried out in Japan by Moroi and colleagues 294 compared a once-daily dose of heat-killed Lactobacillus paracasei K71 for at least 12 weeks against placebo in 34 adults with mild to moderate eczema. There was no significant difference between the groups in change in eczema severity or change in itch scores or quality of life.…”

“…Sixteen [289][290][291][292][293][294][295][296][297][298][299][300][301][302][303][304] new trials were reported after 2000. Nearly all of the 16 trials reported compared a probiotic against an inactive placebo or occasionally against no treatment.…”

“…302 In 13 [289][290][291][292][293][295][296][297][298]300,302 of the 16 trials the participants were children, particularly infants. Only three trials, 294,299,301 conducted in Japan and Italy, included adult participants. Table 62 provides the risk-of-bias assessment for the new studies.…”

Probiotyki w zapobieganiu i leczeniu alergii

“…W 8. i 12. tygodniu badania nasilenie zmian skórnych znacząco zmniejszyło się w grupie suplementowanej. Pacjenci z tej grupy zużywali także mniej leków działających miejscowo [56]. Matsumoto i wsp.…”

Randomized, double-blind, placebo-controlled, parallel-group study of the effect of <i>Lactobacillus paracasei</i> K71 intake on salivary release of secretory immunoglobulin A

“…We recently found that intake of a dietary supplement containing heat-killed L. paracasei K71 was effective in reducing the clinical severity of atopic dermatitis in a randomized controlled trial [13], suggesting that this bacterial strain had immunomodulatory activity. Furthermore, a preliminary clinical study suggested that intake of L. paracasei K71 enhanced secretory immunoglobulin A (sIgA) release in the saliva (unpublished observation).…”